Malaria: Therapeutic implications of melatonin
- Autores
- Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; Brown, Gregory M.; Cardinali, Daniel Pedro
- Año de publicación
- 2010
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.
Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; India
Fil: Spence, David Warren. Canadian Sleep Institute; Canadá
Fil: Moscovitch, Adam. Canadian Sleep Institute; Canadá
Fil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados Unidos
Fil: Trakht, Ilya. Columbia University; Estados Unidos
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina - Materia
-
Apoptosis
Luzindole
Malaria
Melatonin Receptors
Oxidative Stress - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/53543
Ver los metadatos del registro completo
id |
CONICETDig_6d876b305f2f566e3d43f1fedbc5e015 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/53543 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Malaria: Therapeutic implications of melatoninSrinivasan, VenkataramanujanSpence, David WarrenMoscovitch, AdamPandi Perumal, Seithikurippu R.Trakht, IlyaBrown, Gregory M.Cardinali, Daniel PedroApoptosisLuzindoleMalariaMelatonin ReceptorsOxidative Stresshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; IndiaFil: Spence, David Warren. Canadian Sleep Institute; CanadáFil: Moscovitch, Adam. Canadian Sleep Institute; CanadáFil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados UnidosFil: Trakht, Ilya. Columbia University; Estados UnidosFil: Brown, Gregory M.. University of Toronto; CanadáFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaWiley Blackwell Publishing, Inc2010-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/53543Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-80742-3098CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/j.1600-079X.2009.00728.xinfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-079X.2009.00728.xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:23Zoai:ri.conicet.gov.ar:11336/53543instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:24.39CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Malaria: Therapeutic implications of melatonin |
title |
Malaria: Therapeutic implications of melatonin |
spellingShingle |
Malaria: Therapeutic implications of melatonin Srinivasan, Venkataramanujan Apoptosis Luzindole Malaria Melatonin Receptors Oxidative Stress |
title_short |
Malaria: Therapeutic implications of melatonin |
title_full |
Malaria: Therapeutic implications of melatonin |
title_fullStr |
Malaria: Therapeutic implications of melatonin |
title_full_unstemmed |
Malaria: Therapeutic implications of melatonin |
title_sort |
Malaria: Therapeutic implications of melatonin |
dc.creator.none.fl_str_mv |
Srinivasan, Venkataramanujan Spence, David Warren Moscovitch, Adam Pandi Perumal, Seithikurippu R. Trakht, Ilya Brown, Gregory M. Cardinali, Daniel Pedro |
author |
Srinivasan, Venkataramanujan |
author_facet |
Srinivasan, Venkataramanujan Spence, David Warren Moscovitch, Adam Pandi Perumal, Seithikurippu R. Trakht, Ilya Brown, Gregory M. Cardinali, Daniel Pedro |
author_role |
author |
author2 |
Spence, David Warren Moscovitch, Adam Pandi Perumal, Seithikurippu R. Trakht, Ilya Brown, Gregory M. Cardinali, Daniel Pedro |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
Apoptosis Luzindole Malaria Melatonin Receptors Oxidative Stress |
topic |
Apoptosis Luzindole Malaria Melatonin Receptors Oxidative Stress |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed. Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; India Fil: Spence, David Warren. Canadian Sleep Institute; Canadá Fil: Moscovitch, Adam. Canadian Sleep Institute; Canadá Fil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados Unidos Fil: Trakht, Ilya. Columbia University; Estados Unidos Fil: Brown, Gregory M.. University of Toronto; Canadá Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina |
description |
Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-01 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/53543 Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-8 0742-3098 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/53543 |
identifier_str_mv |
Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-8 0742-3098 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1600-079X.2009.00728.x info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-079X.2009.00728.x |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269635767959552 |
score |
13.13397 |